A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia [9]

New England Journal of Medicine

Volumn 348, Issue 22, 2003, Pages 2265-2266

  Roche Lestienne, Catherine ^a   Laï, Jean Luc ^a   Darré, Stéphane ^a   Facon, Thierry ^a   Preudhomme, Claude ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYTARABINE; IMATINIB;

AGED; ALLELISM; BONE MARROW CELL; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CYTOGENETICS; DISEASE COURSE; GENE MUTATION; GENE SEQUENCE; HUMAN; KARYOTYPE 46,XY; LETTER; MALE; METAPHASE; MOLECULAR CLONING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RETROSPECTIVE STUDY; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MALE; PIPERAZINES; POINT MUTATION; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 0038137081     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMc035089     Document Type: Letter

References (3)

1. Gorre ME, Sawyers CL. Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia. Curr Opin Hematol 2002;9:303-7.
2. Roche-Lestienne C, Soenen-Comu V, Grardel-Duflos N, et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can preexist to the onset of treatment. Blood 2002;100:1014-8.
3. Shah N-P, Nicoll J-M, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002;2:117-25.